Bill Sponsor
House Bill 5237
117th Congress(2021-2022)
Reduced Costs and Continued Cures Act of 2021
Introduced
Introduced
Introduced in House on Sep 10, 2021
Overview
Text
Introduced
Sep 10, 2021
Latest Action
Nov 1, 2022
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
5237
Congress
117
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Democrat
California
Democrat
California
House Votes (0)
Senate Votes (0)
No House votes have been held for this bill.
Summary

Reduced Costs and Continued Cures Act of 2021

This bill establishes and alters several programs and requirements relating to the prices of prescription drugs.

For example, the bill establishes and alters several requirements under Medicare and Medicaid, including

  • requiring drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for covered drugs under Medicare that cost $100 or more and for which the average manufacturer price increases faster than inflation,
  • capping annual out-of-pocket spending under the Medicare prescription drug benefit, and
  • increasing the maximum rebate amount under the Medicaid Drug Rebate Program.

The bill also makes changes relating to market exclusivities and manufacturer price concessions for prescription drugs, including

  • authorizing the Federal Trade Commission to initiate proceedings against parties to settlements of patent infringement claims that have anticompetitive effects with respect to drugs or biologics,
  • limiting in certain instances the number of patents that the manufacturer of a biologic can assert in a lawsuit against a company seeking to sell a biosimilar version, and
  • nullifying regulations relating to the treatment of certain Medicare prescription drug benefit rebates from drug manufacturers for purposes of federal anti-kickback laws.
Text (1)
September 10, 2021
Actions (6)
11/01/2022
Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
11/01/2022
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
09/13/2021
Referred to the Subcommittee on Health.
09/10/2021
Referred to the Subcommittee on Health.
09/10/2021
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
09/10/2021
Introduced in House
Public Record
Record Updated
Dec 30, 2022 11:18:35 AM